Connection

RUSSELL BROADDUS to Humans

This is a "connection" page, showing publications RUSSELL BROADDUS has written about Humans.
Connection Strength

0.858
  1. Context-dependent environmental associations with endometrial cancer histotype and genotype. Int J Gynecol Cancer. 2023 08 07; 33(8):1215-1221.
    View in: PubMed
    Score: 0.017
  2. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline From the College of American Pathologists in Collaboration With the Association for Molecular Pathology and Fight Colorectal Cancer. Arch Pathol Lab Med. 2022 10 01; 146(10):1194-1210.
    View in: PubMed
    Score: 0.016
  3. Adjuvant treatment in early-stage endometrial cancer: context-dependent impact of somatic CTNNB1 mutation on recurrence-free survival. Int J Gynecol Cancer. 2022 07 04; 32(7):869-874.
    View in: PubMed
    Score: 0.016
  4. Low grade endometrioid endometrial cancer: complexities beyond p53abn. Int J Gynecol Cancer. 2021 09; 31(9):1312.
    View in: PubMed
    Score: 0.015
  5. Endometrial Cancer. Reply. N Engl J Med. 2021 02 11; 384(6):586.
    View in: PubMed
    Score: 0.015
  6. Endometrial Cancer. N Engl J Med. 2020 11 19; 383(21):2053-2064.
    View in: PubMed
    Score: 0.014
  7. Variable Expression of MSH6 in Endometrial Carcinomas With Intact Mismatch Repair and With MLH1 Loss Due to MLH1 Methylation. Int J Gynecol Pathol. 2020 Nov; 39(6):507-513.
    View in: PubMed
    Score: 0.014
  8. Endometrial cancer with cervical extension in an obese patient: options for surgery versus combined chemoradiotherapy and extra-fascial hysterectomy. Int J Gynecol Cancer. 2019 06; 29(5):976-980.
    View in: PubMed
    Score: 0.013
  9. Molecular Modifiers of Hormone Receptor Action: Decreased Androgen Receptor Expression in Mismatch Repair Deficient Endometrial Endometrioid Adenocarcinoma. Int J Gynecol Pathol. 2019 Jan; 38(1):44-51.
    View in: PubMed
    Score: 0.013
  10. Targeted next-generation sequencing of endometrial cancer and matched circulating tumor DNA: identification of plasma-based, tumor-associated mutations in early stage patients. Mod Pathol. 2019 03; 32(3):405-414.
    View in: PubMed
    Score: 0.012
  11. Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes. Mod Pathol. 2019 03; 32(3):396-404.
    View in: PubMed
    Score: 0.012
  12. Nuclear ?-catenin localization and mutation of the CTNNB1 gene: a context-dependent association. Mod Pathol. 2018 10; 31(10):1553-1559.
    View in: PubMed
    Score: 0.012
  13. CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence. Mod Pathol. 2017 07; 30(7):1032-1041.
    View in: PubMed
    Score: 0.011
  14. Clinical Challenges Associated with Universal Screening for Lynch Syndrome-Associated Endometrial Cancer. Cancer Prev Res (Phila). 2017 Feb; 10(2):108-115.
    View in: PubMed
    Score: 0.011
  15. CD73s protection of epithelial integrity: Thinking beyond the barrier. Tissue Barriers. 2016; 4(4):e1224963.
    View in: PubMed
    Score: 0.011
  16. Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort. Mod Pathol. 2016 11; 29(11):1381-1389.
    View in: PubMed
    Score: 0.011
  17. Laboratory Assays in Evaluation of Lynch Syndrome in Patients with Endometrial Carcinoma. Surg Pathol Clin. 2016 Jun; 9(2):289-99.
    View in: PubMed
    Score: 0.010
  18. Defective DNA Mismatch Repair Influences Expression of Endometrial Carcinoma Biomarkers. Int J Gynecol Pathol. 2016 Jan; 35(1):8-15.
    View in: PubMed
    Score: 0.010
  19. Intact PTEN Expression by Immunohistochemistry is Associated With Decreased Survival in Advanced Stage Ovarian/Primary Peritoneal High-grade Serous Carcinoma. Int J Gynecol Pathol. 2015 Nov; 34(6):497-506.
    View in: PubMed
    Score: 0.010
  20. Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing. Mol Cancer Ther. 2015 Dec; 14(12):2887-95.
    View in: PubMed
    Score: 0.010
  21. Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for Lynch syndrome. Gynecol Oncol. 2014 Aug; 134(2):319-25.
    View in: PubMed
    Score: 0.009
  22. Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer. Cancer Prev Res (Phila). 2014 Jul; 7(7):686-97.
    View in: PubMed
    Score: 0.009
  23. Role of the clinical pathology laboratory in the evaluation of endometrial carcinomas for Lynch syndrome. Semin Diagn Pathol. 2014 May; 31(3):195-204.
    View in: PubMed
    Score: 0.009
  24. Utility of MLH1 methylation analysis in the clinical evaluation of Lynch Syndrome in women with endometrial cancer. Curr Pharm Des. 2014; 20(11):1655-63.
    View in: PubMed
    Score: 0.009
  25. Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with Lynch syndrome. Cancer Prev Res (Phila). 2013 Aug; 6(8):774-81.
    View in: PubMed
    Score: 0.009
  26. Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas. Mod Pathol. 2013 Oct; 26(10):1401-12.
    View in: PubMed
    Score: 0.009
  27. Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. Mod Pathol. 2012 May; 25(5):699-708.
    View in: PubMed
    Score: 0.008
  28. Personalized therapy in endometrial cancer: challenges and opportunities. Cancer Biol Ther. 2012 Jan 01; 13(1):1-13.
    View in: PubMed
    Score: 0.008
  29. Identification of cancer patients with Lynch syndrome: clinically significant discordances and problems in tissue-based mismatch repair testing. Cancer Prev Res (Phila). 2012 Feb; 5(2):320-7.
    View in: PubMed
    Score: 0.008
  30. Molecular clustering based on ERa and EIG121 predicts survival in high-grade serous carcinoma of the ovary/peritoneum. Mod Pathol. 2011 Mar; 24(3):453-62.
    View in: PubMed
    Score: 0.007
  31. Expression of nuclear transcription factor kappa B in locally advanced human cervical cancer treated with definitive chemoradiation. Int J Radiat Oncol Biol Phys. 2010 Dec 01; 78(5):1331-6.
    View in: PubMed
    Score: 0.007
  32. Loss of inhibitory insulin receptor substrate-1 phosphorylation is an early event in mammalian target of rapamycin-dependent endometrial hyperplasia and carcinoma. Cancer Prev Res (Phila). 2010 Mar; 3(3):290-300.
    View in: PubMed
    Score: 0.007
  33. The novel estrogen-induced gene EIG121 regulates autophagy and promotes cell survival under stress. Cell Death Dis. 2010; 1:e32.
    View in: PubMed
    Score: 0.007
  34. S100A4 mediates endometrial cancer invasion and is a target of TGF-beta1 signaling. Lab Invest. 2009 Aug; 89(8):937-47.
    View in: PubMed
    Score: 0.007
  35. Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J Clin Oncol. 2008 Dec 20; 26(36):5965-71.
    View in: PubMed
    Score: 0.006
  36. Gene expression changes in cervical squamous cell carcinoma after initiation of chemoradiation and correlation with clinical outcome. Int J Radiat Oncol Biol Phys. 2008 May 01; 71(1):226-36.
    View in: PubMed
    Score: 0.006
  37. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol. 2007 Nov 20; 25(33):5158-64.
    View in: PubMed
    Score: 0.006
  38. Hypomethylation-induced expression of S100A4 in endometrial carcinoma. Mod Pathol. 2007 Oct; 20(10):1045-54.
    View in: PubMed
    Score: 0.006
  39. Serology- and biopsy-proven celiac disease in a patient with AIDS: case report. Dig Dis Sci. 2007 Jun; 52(6):1448-51.
    View in: PubMed
    Score: 0.006
  40. Women with HNPCC: a target population for the chemoprevention of gynecologic cancers. Front Biosci. 2006 Sep 01; 11:2077-80.
    View in: PubMed
    Score: 0.005
  41. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer. 2006 Jan 01; 106(1):87-94.
    View in: PubMed
    Score: 0.005
  42. Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia. Gynecol Oncol. 2005 Nov; 99(2):472-6.
    View in: PubMed
    Score: 0.005
  43. Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol. 2005 Mar; 105(3):569-74.
    View in: PubMed
    Score: 0.005
  44. Gynecologic Cancers in Lynch Syndrome/HNPCC. Fam Cancer. 2005; 4(3):249-54.
    View in: PubMed
    Score: 0.005
  45. Unusual tumors associated with the hereditary nonpolyposis colorectal cancer syndrome. Mod Pathol. 2004 Aug; 17(8):981-9.
    View in: PubMed
    Score: 0.005
  46. The chemopreventive agents 4-HPR and DFMO inhibit growth and induce apoptosis in uterine leiomyomas. Am J Obstet Gynecol. 2004 Mar; 190(3):686-92.
    View in: PubMed
    Score: 0.005
  47. Neuroendocrine tumors (carcinoid and neuroendocrine carcinoma) presenting at extra-appendiceal sites in childhood and adolescence. Arch Pathol Lab Med. 2003 Sep; 127(9):1200-3.
    View in: PubMed
    Score: 0.004
  48. A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed m?llerian tumors with evaluation of potential molecular targets. Gynecol Oncol. 2003 Sep; 90(3):529-36.
    View in: PubMed
    Score: 0.004
  49. Comparative Tumor Microenvironment Analysis of Primary and Recurrent Ovarian Granulosa Cell Tumors. Mol Cancer Res. 2023 05 01; 21(5):483-494.
    View in: PubMed
    Score: 0.004
  50. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline. J Clin Oncol. 2023 04 01; 41(10):1943-1948.
    View in: PubMed
    Score: 0.004
  51. MIG-6 Is Critical for Progesterone Responsiveness in Human Complex Atypical Hyperplasia and Early-Stage Endometrial Cancer. Int J Mol Sci. 2022 Nov 23; 23(23).
    View in: PubMed
    Score: 0.004
  52. Wolffian duct tumors: case reports and review of the literature. Gynecol Oncol. 2002 Aug; 86(2):225-30.
    View in: PubMed
    Score: 0.004
  53. Metastatic renal cell carcinoma presenting as a hemorrhoid. Arch Pathol Lab Med. 2002 Jul; 126(7):856-8.
    View in: PubMed
    Score: 0.004
  54. Differences in the microbial profiles of early stage endometrial cancers between Black and White women. Gynecol Oncol. 2022 05; 165(2):248-256.
    View in: PubMed
    Score: 0.004
  55. Factors Impacting Clinically Relevant RNA Fusion Assays Using Next-Generation Sequencing. Arch Pathol Lab Med. 2021 11 01; 145(11):1405-1412.
    View in: PubMed
    Score: 0.004
  56. Gynecological tumors in hereditary nonpolyposis colorectal cancer: We know they are common--now what? Gynecol Oncol. 2001 Aug; 82(2):221-2.
    View in: PubMed
    Score: 0.004
  57. Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer. Clin Cancer Res. 2021 08 15; 27(16):4587-4598.
    View in: PubMed
    Score: 0.004
  58. Clinical significance of homologous recombination deficiency score testing in endometrial Cancer. Gynecol Oncol. 2021 03; 160(3):777-785.
    View in: PubMed
    Score: 0.004
  59. Evaluating Mismatch Repair/Microsatellite Instability Status Using Cytology Effusion Specimens to Determine Eligibility for Immunotherapy. Arch Pathol Lab Med. 2021 01 01; 145(1):46-54.
    View in: PubMed
    Score: 0.004
  60. Utilization of cytology smears improves success rates of RNA-based next-generation sequencing gene fusion assays for clinically relevant predictive biomarkers. Cancer Cytopathol. 2021 05; 129(5):374-382.
    View in: PubMed
    Score: 0.004
  61. Endometrial biomarkers in premenopausal women with obesity: an at-risk cohort. Am J Obstet Gynecol. 2021 03; 224(3):278.e1-278.e14.
    View in: PubMed
    Score: 0.004
  62. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 02; 224(2):191.e1-191.e15.
    View in: PubMed
    Score: 0.004
  63. Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. Cancer Cell. 2020 03 16; 37(3):371-386.e12.
    View in: PubMed
    Score: 0.003
  64. Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Sci Rep. 2020 02 20; 10(1):3080.
    View in: PubMed
    Score: 0.003
  65. Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. J Hematol Oncol. 2019 12 30; 12(1):145.
    View in: PubMed
    Score: 0.003
  66. Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer. Int J Cancer. 2020 07 15; 147(2):413-422.
    View in: PubMed
    Score: 0.003
  67. Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study. Clin Cancer Res. 2020 02 01; 26(3):581-587.
    View in: PubMed
    Score: 0.003
  68. Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland. Virchows Arch. 2020 Feb; 476(2):295-305.
    View in: PubMed
    Score: 0.003
  69. G-protein coupled receptor 64 (GPR64) acts as a tumor suppressor in endometrial cancer. BMC Cancer. 2019 Aug 14; 19(1):810.
    View in: PubMed
    Score: 0.003
  70. Genetic profiling as a clinical tool in advanced parathyroid carcinoma. J Cancer Res Clin Oncol. 2019 Aug; 145(8):1977-1986.
    View in: PubMed
    Score: 0.003
  71. Liquid biopsy assay for lung carcinoma using centrifuged supernatants from fine-needle aspiration specimens. Ann Oncol. 2019 06 01; 30(6):963-969.
    View in: PubMed
    Score: 0.003
  72. Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer. Gynecol Oncol. 2019 07; 154(1):22-28.
    View in: PubMed
    Score: 0.003
  73. Microsatellite Instability Occurs in a Subset of Follicular Thyroid Cancers. Thyroid. 2019 04; 29(4):523-529.
    View in: PubMed
    Score: 0.003
  74. Clinical and molecular characterization of early-onset colorectal cancer. Cancer. 2019 06 15; 125(12):2002-2010.
    View in: PubMed
    Score: 0.003
  75. Pleiotropic Effects of PPARD Accelerate Colorectal Tumorigenesis, Progression, and Invasion. Cancer Res. 2019 03 01; 79(5):954-969.
    View in: PubMed
    Score: 0.003
  76. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A. 2019 01 29; 116(5):1692-1697.
    View in: PubMed
    Score: 0.003
  77. Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer. J Natl Cancer Inst. 2018 12 01; 110(12):1409-1417.
    View in: PubMed
    Score: 0.003
  78. Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. Clin Colorectal Cancer. 2018 12; 17(4):e699-e709.
    View in: PubMed
    Score: 0.003
  79. KMT2D/MLL2 inactivation is associated with recurrence in adult-type granulosa cell tumors of the ovary. Nat Commun. 2018 06 27; 9(1):2496.
    View in: PubMed
    Score: 0.003
  80. MIG-6 suppresses endometrial epithelial cell proliferation by inhibiting phospho-AKT. BMC Cancer. 2018 May 29; 18(1):605.
    View in: PubMed
    Score: 0.003
  81. Challenges in next generation sequencing analysis of somatic mutations in transplant patients. Cancer Genet. 2018 10; 226-227:17-22.
    View in: PubMed
    Score: 0.003
  82. Prospective Randomized Biomarker Study of Metformin and Lifestyle Intervention for Prevention in Obese Women at Increased Risk for Endometrial Cancer. Cancer Prev Res (Phila). 2018 08; 11(8):477-490.
    View in: PubMed
    Score: 0.003
  83. Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing Tumors Beyond Diagnosis for Targeted Therapy. Mol Cancer Ther. 2018 07; 17(7):1575-1584.
    View in: PubMed
    Score: 0.003
  84. Salvaging the supernatant: next generation cytopathology for solid tumor mutation profiling. Mod Pathol. 2018 07; 31(7):1036-1045.
    View in: PubMed
    Score: 0.003
  85. Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device. Obstet Gynecol. 2018 01; 131(1):109-116.
    View in: PubMed
    Score: 0.003
  86. Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Mol Cancer Ther. 2018 02; 17(2):464-473.
    View in: PubMed
    Score: 0.003
  87. Loss of polarity alters proliferation and differentiation in low-grade endometrial cancers by disrupting Notch signaling. PLoS One. 2017; 12(12):e0189081.
    View in: PubMed
    Score: 0.003
  88. Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. Clin Cancer Res. 2018 03 01; 24(5):1062-1072.
    View in: PubMed
    Score: 0.003
  89. Importance of PCR-based Tumor Testing in the Evaluation of Lynch Syndrome-associated Endometrial Cancer. Adv Anat Pathol. 2017 Nov; 24(6):372-378.
    View in: PubMed
    Score: 0.003
  90. MIG-6 negatively regulates STAT3 phosphorylation in uterine epithelial cells. Oncogene. 2018 01 11; 37(2):255-262.
    View in: PubMed
    Score: 0.003
  91. Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial. Clin Cancer Res. 2018 02 01; 24(3):521-531.
    View in: PubMed
    Score: 0.003
  92. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. Nat Med. 2017 09; 23(9):1046-1054.
    View in: PubMed
    Score: 0.003
  93. Universal Point of Care Testing for Lynch Syndrome in Patients with Upper Tract Urothelial Carcinoma. J Urol. 2018 01; 199(1):60-65.
    View in: PubMed
    Score: 0.003
  94. A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. Oncotarget. 2017 Jun 27; 8(26):41806-41814.
    View in: PubMed
    Score: 0.003
  95. Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget. 2017 May 16; 8(20):33796-33806.
    View in: PubMed
    Score: 0.003
  96. Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid. J Mol Diagn. 2017 07; 19(4):514-524.
    View in: PubMed
    Score: 0.003
  97. Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing. Cancer. 2017 Sep 01; 123(17):3261-3268.
    View in: PubMed
    Score: 0.003
  98. Factors prognostic of survival in advanced-stage uterine serous carcinoma. Gynecol Oncol. 2017 07; 146(1):27-33.
    View in: PubMed
    Score: 0.003
  99. Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Endometrium. Arch Pathol Lab Med. 2017 11; 141(11):1508-1512.
    View in: PubMed
    Score: 0.003
  100. Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters. Clin Cancer Res. 2017 Aug 01; 23(15):4473-4481.
    View in: PubMed
    Score: 0.003
  101. Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray. Oncotarget. 2017 02 14; 8(7):10845-10857.
    View in: PubMed
    Score: 0.003
  102. Concurrent fine needle aspirations and core needle biopsies: a comparative study of substrates for next-generation sequencing in solid organ malignancies. Mod Pathol. 2017 04; 30(4):499-508.
    View in: PubMed
    Score: 0.003
  103. Metastasis regulation by PPARD expression in cancer cells. JCI Insight. 2017 01 12; 2(1):e91419.
    View in: PubMed
    Score: 0.003
  104. A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors. J Mol Diagn. 2017 03; 19(2):255-264.
    View in: PubMed
    Score: 0.003
  105. MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis. J Hematol Oncol. 2016 10 19; 9(1):112.
    View in: PubMed
    Score: 0.003
  106. Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study. Gynecol Oncol. 2016 Dec; 143(3):466-471.
    View in: PubMed
    Score: 0.003
  107. Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma. J Pathol. 2016 09; 240(1):84-95.
    View in: PubMed
    Score: 0.003
  108. How Do We Make Clinical Molecular Testing for Cancer Standard of Care for Pathology Departments? J Natl Compr Canc Netw. 2016 06; 14(6):787-92.
    View in: PubMed
    Score: 0.003
  109. MUC1 stimulates EGFR expression and function in endometrial cancer. Oncotarget. 2016 May 31; 7(22):32796-809.
    View in: PubMed
    Score: 0.003
  110. Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer. 2016 06 15; 122(12):1836-43.
    View in: PubMed
    Score: 0.003
  111. Identification of Factors Affecting the Success of Next-Generation Sequencing Testing in Solid Tumors. Am J Clin Pathol. 2016 Feb; 145(2):222-37.
    View in: PubMed
    Score: 0.003
  112. The Genomic Heterogeneity of FIGO Grade 3 Endometrioid Carcinoma Impacts Diagnostic Accuracy and Reproducibility. Int J Gynecol Pathol. 2016 Jan; 35(1):16-24.
    View in: PubMed
    Score: 0.003
  113. Loss of p27 Associated with Risk for Endometrial Carcinoma Arising in the Setting of Obesity. Curr Mol Med. 2016; 16(3):252-65.
    View in: PubMed
    Score: 0.003
  114. Long non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations. Oncotarget. 2015 Nov 24; 6(37):39865-76.
    View in: PubMed
    Score: 0.003
  115. Cytokine stimulation of MUC4 expression in human female reproductive tissue carcinoma cell lines and endometrial cancer. J Cell Biochem. 2015 Nov; 116(11):2649-57.
    View in: PubMed
    Score: 0.003
  116. Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. Am J Clin Pathol. 2015 Nov; 144(5):713-21.
    View in: PubMed
    Score: 0.003
  117. Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 2015 Aug 21; 6(24):20099-110.
    View in: PubMed
    Score: 0.002
  118. Factors affecting the success of next-generation sequencing in cytology specimens. Cancer Cytopathol. 2015 Nov; 123(11):659-68.
    View in: PubMed
    Score: 0.002
  119. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. JAMA Oncol. 2015 Jul; 1(4):486-94.
    View in: PubMed
    Score: 0.002
  120. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy. Mod Pathol. 2015 Sep; 28(9):1225-35.
    View in: PubMed
    Score: 0.002
  121. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol. 2015 Sep 01; 33(25):2753-62.
    View in: PubMed
    Score: 0.002
  122. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. Mol Oncol. 2015 Oct; 9(8):1694-703.
    View in: PubMed
    Score: 0.002
  123. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Hum Pathol. 2015 Aug; 46(8):1101-10.
    View in: PubMed
    Score: 0.002
  124. A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst. 2015 Jul; 107(7).
    View in: PubMed
    Score: 0.002
  125. Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations. J Cutan Pathol. 2015 May; 42(5):308-17.
    View in: PubMed
    Score: 0.002
  126. Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clin Cancer Res. 2015 Jun 01; 21(11):2644-51.
    View in: PubMed
    Score: 0.002
  127. Identifying aggressive forms of endometrioid-type endometrial cancer: new insights into molecular subtyping. Expert Rev Anticancer Ther. 2015 Jan; 15(1):1-3.
    View in: PubMed
    Score: 0.002
  128. Mig-6 suppresses endometrial cancer associated with Pten deficiency and ERK activation. Cancer Res. 2014 Dec 15; 74(24):7371-82.
    View in: PubMed
    Score: 0.002
  129. OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets. Mol Cancer. 2014 Oct 24; 13:241.
    View in: PubMed
    Score: 0.002
  130. Is it all Lynch syndrome?: An assessment of family history in individuals with mismatch repair-deficient tumors. Genet Med. 2015 Jun; 17(6):476-84.
    View in: PubMed
    Score: 0.002
  131. Role of microsatellite instability-low as a diagnostic biomarker of Lynch syndrome in colorectal cancer. Cancer Genet. 2014 Oct-Dec; 207(10-12):495-502.
    View in: PubMed
    Score: 0.002
  132. Clinically significant endometrial cancer risk following a diagnosis of complex atypical hyperplasia. Gynecol Oncol. 2014 Dec; 135(3):451-4.
    View in: PubMed
    Score: 0.002
  133. Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors. Cancer Cell. 2014 Oct 13; 26(4):479-94.
    View in: PubMed
    Score: 0.002
  134. Expression of estrogen-induced genes and estrogen receptor ? in pancreatic neuroendocrine tumors: implications for targeted therapy. Pancreas. 2014 Oct; 43(7):996-1002.
    View in: PubMed
    Score: 0.002
  135. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. J Natl Cancer Inst. 2014 Sep; 106(9).
    View in: PubMed
    Score: 0.002
  136. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin Cancer Res. 2014 Nov 01; 20(21):5527-36.
    View in: PubMed
    Score: 0.002
  137. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015 Feb; 135(2):508-515.
    View in: PubMed
    Score: 0.002
  138. Combined colonoscopy and endometrial biopsy cancer screening results in women with Lynch syndrome. Gynecol Oncol. 2014 Oct; 135(1):85-9.
    View in: PubMed
    Score: 0.002
  139. Progesterone receptor and PTEN expression predict survival in patients with low- and intermediate-grade pancreatic neuroendocrine tumors. Arch Pathol Lab Med. 2014 Aug; 138(8):1027-36.
    View in: PubMed
    Score: 0.002
  140. Fallopian tube high-grade serous carcinoma with intramucosal spread and presenting as a malignancy on pap smear. Int J Gynecol Pathol. 2014 Jul; 33(4):443-8.
    View in: PubMed
    Score: 0.002
  141. The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer. Int J Gynecol Cancer. 2014 May; 24(4):713-7.
    View in: PubMed
    Score: 0.002
  142. CGRRF1 as a novel biomarker of tissue response to metformin in the context of obesity. Gynecol Oncol. 2014 Apr; 133(1):83-9.
    View in: PubMed
    Score: 0.002
  143. Potentiation of colon cancer susceptibility in mice by colonic epithelial PPAR-d/? overexpression. J Natl Cancer Inst. 2014 Apr; 106(4):dju052.
    View in: PubMed
    Score: 0.002
  144. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol. 2014 May; 25(5):1032-8.
    View in: PubMed
    Score: 0.002
  145. Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib. Clin Cancer Res. 2014 Apr 01; 20(7):1846-55.
    View in: PubMed
    Score: 0.002
  146. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. 2014 Jan 30; 6(2):377-87.
    View in: PubMed
    Score: 0.002
  147. Human omental-derived adipose stem cells increase ovarian cancer proliferation, migration, and chemoresistance. PLoS One. 2013; 8(12):e81859.
    View in: PubMed
    Score: 0.002
  148. HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival. Int J Mol Sci. 2013 Nov 18; 14(11):22655-77.
    View in: PubMed
    Score: 0.002
  149. Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma. Hum Pathol. 2013 Dec; 44(12):2792-8.
    View in: PubMed
    Score: 0.002
  150. ?-Catenin activation contributes to the pathogenesis of adenomyosis through epithelial-mesenchymal transition. J Pathol. 2013 Oct; 231(2):210-22.
    View in: PubMed
    Score: 0.002
  151. Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy. Mol Cancer Ther. 2013 Dec; 12(12):2847-56.
    View in: PubMed
    Score: 0.002
  152. Molecular pathogenesis of endometrial cancers in patients with Lynch syndrome. Cancer. 2013 Aug 15; 119(16):3027-33.
    View in: PubMed
    Score: 0.002
  153. Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May 02; 497(7447):67-73.
    View in: PubMed
    Score: 0.002
  154. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 2013 Feb 11; 23(2):186-99.
    View in: PubMed
    Score: 0.002
  155. Genomic loss of tumor suppressor miRNA-204 promotes cancer cell migration and invasion by activating AKT/mTOR/Rac1 signaling and actin reorganization. PLoS One. 2012; 7(12):e52397.
    View in: PubMed
    Score: 0.002
  156. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. 2012 Nov 06; 107(10):1776-82.
    View in: PubMed
    Score: 0.002
  157. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res. 2012 Nov; 22(11):2120-9.
    View in: PubMed
    Score: 0.002
  158. Integrated analysis of gene expression and tumor nuclear image profiles associated with chemotherapy response in serous ovarian carcinoma. PLoS One. 2012; 7(5):e36383.
    View in: PubMed
    Score: 0.002
  159. Somatic deletions of the polyA tract in the 3' untranslated region of epidermal growth factor receptor are common in microsatellite instability-high endometrial and colorectal carcinomas. Arch Pathol Lab Med. 2012 May; 136(5):510-6.
    View in: PubMed
    Score: 0.002
  160. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. Gynecol Oncol. 2012 Jun; 125(3):640-5.
    View in: PubMed
    Score: 0.002
  161. Progestin intrauterine device in an adolescent with grade 2 endometrial cancer. Obstet Gynecol. 2012 Feb; 119(2 Pt 2):423-426.
    View in: PubMed
    Score: 0.002
  162. Uterine serous carcinoma: increased familial risk for lynch-associated malignancies. Cancer Prev Res (Phila). 2012 Mar; 5(3):435-43.
    View in: PubMed
    Score: 0.002
  163. Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible. Int J Gynecol Pathol. 2012 Jan; 31(1):48-56.
    View in: PubMed
    Score: 0.002
  164. Omental adipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors. Clin Cancer Res. 2012 Feb 01; 18(3):771-82.
    View in: PubMed
    Score: 0.002
  165. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 2011 Jul; 1(2):170-85.
    View in: PubMed
    Score: 0.002
  166. Acute-onset ectopic adrenocorticotropic hormone syndrome secondary to metastatic endometrioid carcinoma of the ovaries as a fatal complication. J Clin Oncol. 2011 Jun 01; 29(16):e462-4.
    View in: PubMed
    Score: 0.002
  167. Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinoma. Cancer. 2011 Aug 15; 117(16):3741-9.
    View in: PubMed
    Score: 0.002
  168. Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol Ther. 2010 Dec 15; 10(12):1306-14.
    View in: PubMed
    Score: 0.002
  169. Sex hormone regulation of survivin gene expression. J Endocrinol. 2010 Nov; 207(2):237-43.
    View in: PubMed
    Score: 0.002
  170. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010 Dec 01; 116(23):5415-9.
    View in: PubMed
    Score: 0.002
  171. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol. 2010 Aug 01; 28(22):3570-6.
    View in: PubMed
    Score: 0.002
  172. Genomic characterization of gene copy-number aberrations in endometrial carcinoma cell lines derived from endometrioid-type endometrial adenocarcinoma. Technol Cancer Res Treat. 2010 Apr; 9(2):179-89.
    View in: PubMed
    Score: 0.002
  173. Primary peritoneal cancer after bilateral salpingo-oophorectomy in two patients with Lynch syndrome. Obstet Gynecol. 2010 Feb; 115(2 Pt 2):432-434.
    View in: PubMed
    Score: 0.002
  174. Microscopic evaluation of lymph-node-bearing tissue in early-stage cervical cancer: a dual-institution review. Ann Surg Oncol. 2010 Apr; 17(4):1106-10.
    View in: PubMed
    Score: 0.002
  175. Molecular clustering of endometrial carcinoma based on estrogen-induced gene expression. Cancer Biol Ther. 2009 Nov; 8(22):2126-35.
    View in: PubMed
    Score: 0.002
  176. EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer. 2009 Jun 15; 115(12):2684-92.
    View in: PubMed
    Score: 0.002
  177. Mig-6 modulates uterine steroid hormone responsiveness and exhibits altered expression in endometrial disease. Proc Natl Acad Sci U S A. 2009 May 26; 106(21):8677-82.
    View in: PubMed
    Score: 0.002
  178. Targeted genetic disruption of peroxisome proliferator-activated receptor-delta and colonic tumorigenesis. J Natl Cancer Inst. 2009 May 20; 101(10):762-7.
    View in: PubMed
    Score: 0.002
  179. Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma. Cancer. 2009 May 01; 115(9):1867-74.
    View in: PubMed
    Score: 0.002
  180. Clinicopathological features in endometrial carcinoma associated with Lynch syndrome in China. Int J Gynecol Cancer. 2009 May; 19(4):651-6.
    View in: PubMed
    Score: 0.002
  181. DNA methylation inhibits p53-mediated survivin repression. Oncogene. 2009 May 14; 28(19):2046-50.
    View in: PubMed
    Score: 0.002
  182. Spermatogenesis associated retrogenes are expressed in the human ovary and ovarian cancers. PLoS One. 2009; 4(3):e5064.
    View in: PubMed
    Score: 0.002
  183. 15-LOX-1 transcription suppression through the NuRD complex in colon cancer cells. Oncogene. 2009 Mar 26; 28(12):1496-505.
    View in: PubMed
    Score: 0.002
  184. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control. 2009 Jan; 16(1):14-22.
    View in: PubMed
    Score: 0.002
  185. Genetic variation in genes for the xenobiotic-metabolizing enzymes CYP1A1, EPHX1, GSTM1, GSTT1, and GSTP1 and susceptibility to colorectal cancer in Lynch syndrome. Cancer Epidemiol Biomarkers Prev. 2008 Sep; 17(9):2393-401.
    View in: PubMed
    Score: 0.002
  186. AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27. Cancer Res. 2008 Aug 15; 68(16):6496-506.
    View in: PubMed
    Score: 0.002
  187. MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers. Oncogene. 2008 Nov 06; 27(52):6667-78.
    View in: PubMed
    Score: 0.002
  188. Role of PELP1/MNAR signaling in ovarian tumorigenesis. Cancer Res. 2008 Jun 15; 68(12):4902-9.
    View in: PubMed
    Score: 0.002
  189. ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. Mod Pathol. 2008 Jul; 21(7):912-23.
    View in: PubMed
    Score: 0.002
  190. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma. Clin Cancer Res. 2008 May 01; 14(9):2543-50.
    View in: PubMed
    Score: 0.002
  191. Primary liver sarcoma in an immunocompetent patient with hepatitis C virus infection. Am J Clin Oncol. 2008 Apr; 31(2):207-8.
    View in: PubMed
    Score: 0.001
  192. Fusion of circulating blood cells with solid-organ tissue cells in clinical stem cell transplants: a potential therapeutic model? Regen Med. 2008 Mar; 3(2):157-64.
    View in: PubMed
    Score: 0.001
  193. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res. 2007 Dec 15; 13(24):7487-95.
    View in: PubMed
    Score: 0.001
  194. Multifocal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation. Neuro Oncol. 2008 Feb; 10(1):93-7.
    View in: PubMed
    Score: 0.001
  195. Influence of methylenetetrahydrofolate reductase gene polymorphisms C677T and A1298C on age-associated risk for colorectal cancer in a caucasian lynch syndrome population. Cancer Epidemiol Biomarkers Prev. 2007 Sep; 16(9):1753-9.
    View in: PubMed
    Score: 0.001
  196. Preoperative lymph-vascular space invasion is associated with nodal metastases in women with early-stage cervical cancer. Gynecol Oncol. 2007 Jul; 106(1):12-5.
    View in: PubMed
    Score: 0.001
  197. Loss of phosphatase and tensin homologue deleted on chromosome 10 and phosphorylation of mammalian target of rapamycin are associated with progesterone refractory endometrial hyperplasia. Int J Gynecol Cancer. 2008 Jan-Feb; 18(1):146-51.
    View in: PubMed
    Score: 0.001
  198. The transcription factor GATA-6 is overexpressed in vivo and contributes to silencing 15-LOX-1 in vitro in human colon cancer. FASEB J. 2007 Mar; 21(3):743-53.
    View in: PubMed
    Score: 0.001
  199. Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. Clin Cancer Res. 2006 Nov 01; 12(21):6373-8.
    View in: PubMed
    Score: 0.001
  200. The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. Cancer Biol Ther. 2006 Sep; 5(9):1136-41.
    View in: PubMed
    Score: 0.001
  201. Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. Gynecol Oncol. 2007 Jan; 104(1):100-3.
    View in: PubMed
    Score: 0.001
  202. Expression of metastasis-associated protein 1 (MTA1) in benign endometrium and endometrial adenocarcinomas. Hum Pathol. 2006 Jun; 37(6):656-61.
    View in: PubMed
    Score: 0.001
  203. The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers. Cancer Res. 2006 Apr 01; 66(7):3893-902.
    View in: PubMed
    Score: 0.001
  204. Deregulation of the HOXA10 homeobox gene in endometrial carcinoma: role in epithelial-mesenchymal transition. Cancer Res. 2006 Jan 15; 66(2):889-97.
    View in: PubMed
    Score: 0.001
  205. Women with synchronous primary cancers of the endometrium and ovary: do they have Lynch syndrome? J Clin Oncol. 2005 Dec 20; 23(36):9344-50.
    View in: PubMed
    Score: 0.001
  206. The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis. Cancer Res. 2005 Dec 15; 65(24):11486-92.
    View in: PubMed
    Score: 0.001
  207. Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform A and p16 genes are associated with metastasis. Mod Pathol. 2005 Dec; 18(12):1632-40.
    View in: PubMed
    Score: 0.001
  208. Identification of a novel estrogen-regulated gene, EIG121, induced by hormone replacement therapy and differentially expressed in type I and type II endometrial cancer. Clin Cancer Res. 2005 Dec 01; 11(23):8258-64.
    View in: PubMed
    Score: 0.001
  209. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol. 2006 Apr; 101(1):126-31.
    View in: PubMed
    Score: 0.001
  210. Undifferentiated carcinoma of the endometrium. Am J Surg Pathol. 2005 Oct; 29(10):1316-21.
    View in: PubMed
    Score: 0.001
  211. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res. 2005 Sep 01; 11(17):6116-26.
    View in: PubMed
    Score: 0.001
  212. Functional regulation of oestrogen receptor pathway by the dynein light chain 1. EMBO Rep. 2005 Jun; 6(6):538-44.
    View in: PubMed
    Score: 0.001
  213. Imatinib mesylate (gleevec)--targeted kinases are expressed in uterine sarcomas. Appl Immunohistochem Mol Morphol. 2005 Jun; 13(2):167-70.
    View in: PubMed
    Score: 0.001
  214. BRAF mutations in aberrant crypt foci and hyperplastic polyposis. Am J Pathol. 2005 Apr; 166(4):1069-75.
    View in: PubMed
    Score: 0.001
  215. Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumors. J Clin Endocrinol Metab. 2004 Dec; 89(12):6130-8.
    View in: PubMed
    Score: 0.001
  216. An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients. Oncogene. 2004 Nov 25; 23(55):8859-67.
    View in: PubMed
    Score: 0.001
  217. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma. Gynecol Oncol. 2004 Oct; 95(1):32-6.
    View in: PubMed
    Score: 0.001
  218. Frozen section analyses as predictors of lymphatic spread in patients with early-stage uterine cancer. J Am Coll Surg. 2004 Sep; 199(3):388-93.
    View in: PubMed
    Score: 0.001
  219. Atypical sigmoid metastasis from a high-grade mixed adenocarcinoma of the ovary. Gynecol Oncol. 2004 Sep; 94(3):850-3.
    View in: PubMed
    Score: 0.001
  220. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol. 2004 Aug 01; 22(15):3126-32.
    View in: PubMed
    Score: 0.001
  221. Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol. 2004 Aug; 94(2):456-62.
    View in: PubMed
    Score: 0.001
  222. Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. Hum Pathol. 2004 May; 35(5):552-9.
    View in: PubMed
    Score: 0.001
  223. Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 2004 May; 13(5):748-52.
    View in: PubMed
    Score: 0.001
  224. HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Int J Cancer. 2004 Feb 10; 108(4):540-8.
    View in: PubMed
    Score: 0.001
  225. Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer. Mod Pathol. 2004 Jan; 17(1):75-80.
    View in: PubMed
    Score: 0.001
  226. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol. 2003 Dec; 91(3):463-9.
    View in: PubMed
    Score: 0.001
  227. Unexpected endometrial cancer at prophylactic hysterectomy in a woman with hereditary nonpolyposis colon cancer. Obstet Gynecol. 2003 Nov; 102(5 Pt 2):1152-5.
    View in: PubMed
    Score: 0.001
  228. Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 1):3534-45.
    View in: PubMed
    Score: 0.001
  229. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer. 2003 Aug 15; 98(4):758-64.
    View in: PubMed
    Score: 0.001
  230. Sarcomatoid carcinoma of the cervix. Gynecol Oncol. 2003 Jul; 90(1):23-8.
    View in: PubMed
    Score: 0.001
  231. Ovarian sex cord-stromal tumors: an immunohistochemical study including a comparison of calretinin and inhibin. Mod Pathol. 2003 Jun; 16(6):584-90.
    View in: PubMed
    Score: 0.001
  232. Coordinate regulation of the production and signaling of retinoic acid by estrogen in the human endometrium. J Clin Endocrinol Metab. 2003 May; 88(5):2157-63.
    View in: PubMed
    Score: 0.001
  233. Inhibition of proliferation and estrogen receptor signaling by peroxisome proliferator-activated receptor gamma ligands in uterine leiomyoma. Cancer Res. 2003 Mar 15; 63(6):1221-7.
    View in: PubMed
    Score: 0.001
  234. Endometrial endometrioid adenocarcinoma in a premenopausal woman presenting with metastasis to bone: a case report and review of the literature. Int J Gynecol Pathol. 2002 Jul; 21(3):281-4.
    View in: PubMed
    Score: 0.001
  235. CpG island methylation in aberrant crypt foci of the colorectum. Am J Pathol. 2002 May; 160(5):1823-30.
    View in: PubMed
    Score: 0.001
  236. Low-grade ovarian cancer in an adolescent patient. Gynecol Oncol. 2001 Jan; 80(1):104-6.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.